Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer.

Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, UCLA David Geffen School of Medicine, Los Angeles, California 90095-6942, USA.
Journal of Nuclear Medicine (Impact Factor: 5.56). 04/2005; 46(4):587-95.
Source: PubMed

ABSTRACT The aim of this study was to compare PET with (18)F-FDG PET, in-line PET/CT, and software fusion of independently acquired CT and PET scans for staging of recurrent colorectal cancer (CRC).
Fifty-one patients with suspected recurrent CRC were studied with in-line PET/CT. Thirty-four of these patients underwent an additional CT scan of the chest or abdomen within 4 wk of PET/CT. Software fusion of PET and CT was performed using a fully automated, intensity-based algorithm. The accuracy of the coregistration of PET and CT scans was evaluated by measuring the distance between landmarks visible in the PET and CT images. Histologic evaluation and follow-up for 6 mo served as the gold standard for the presence or absence of recurrent CRC.
On a patient basis, the accuracy of staging was significantly higher for in-line PET/CT than for PET (88% vs. 71%, P = 0.01). Software fusion of the independently acquired PET and CT images was unsuccessful in 8 patients (24%). In the remaining patients, the mean distance between 62 landmarks visible in PET and CT was 12.9 +/- 7.9 mm, whereas it was only 7.7 +/- 4.7 mm for in-line PET/CT (P < 0.001).
In patients with suspected recurrent CRC, in-line PET/CT significantly improves staging compared with PET alone. Due to its high failure rate, software fusion of independently acquired PET and CT studies cannot be considered to represent an alternative to in-line PET/CT.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Modern imaging techniques have an important role in the diagnostic procedures of malignancies, and assessing response to therapy. The 18F-FDG PET/CT revolutionized the evaluation of colorectal cancer in terms of preoperative staging and monitoring of recurrence. Conventional imaging techniques have limitations in early assessment of response to therapy. 18F-FDG PET has been shown to allow earlier treatment monitoring, because the metabolic change appears before any anatomic change occurs. The Response Evaluation Criteria in Solid Tumours (RECIST) are widely applied, but they have some limitations. There are new international guidelines for treatment response assessment using PET/CT in solid tumours. The authors review indications and the role of hybrid PET/CT in colorectal cancer. Orv. Hetil., 2013, 154, 1447-1453.
    Orvosi Hetilap 09/2013; 154(37):1447-53. DOI:10.1556/OH.2013.29700
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: We evaluated the prognostic value of (18)F-2-fluoro-2-deoxyglucose positron emission tomography (FDG PET) in patients with resectable pancreatic cancer. Materials and Methods: We retrospectively reviewed the medical records of pancreatic cancer patients who underwent curative resection, which included 64 consecutive patients who had preoperative FDG PET scans. For statistical analysis, the maximal standardized uptake value (SUVmax) of primary pancreatic cancer was measured. Survival time was estimated by the Kaplan-Meier method, and Cox's proportional hazard model was used to determine whether SUVmax added new predictive information concerning survival together with known prognostic factors. p<0.05 indicated statistical significance. Results: Overall survival (OS) and disease- free survival (DFS) were respectively 42.9 months (27.6-58.2; 95% CI) and 14.9 months (10.1-19.7; 95% CI). When subjects were divided into two groups according to SUVmax with a cutoff value of 3.5, the high SUVmax group (n=32; SUVmax >3.5) showed significantly shorter OS and DFS than the low SUVmax group. Multivariate analysis of OS and DFS showed that both high SUVmax and poor tumor differentiation were independent poor prognostic factors. Conclusion: Our study showed that degree of FDG uptake was an independent prognostic factor in pancreatic cancer patients who underwent curative resection.
    Yonsei medical journal 11/2013; 54(6):1377-83. DOI:10.3349/ymj.2013.54.6.1377 · 1.26 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: PurposeTo evaluate the usefulness of PET/CT in detecting recurrent colorectal carcinoma (CRCR) in patients subsequent to colonic resection or rectal amputation and to compare it with the PET part of integrated FDG-PET/CT.Materials and methodsPET/CTs from 32 patients with suspected CRCR were studied. Histology, clinical follow-up and additional imaging served as the gold standard. The sensitivity, specificity, positive and negative predictive values (PPV, NPV), and accuracy of PET as well as integrated PET/CT were calculated and compared for each of (a) intra-abdominal extra-hepatic recurrences, (b) extra-abdominal and/or hepatic recurrences, and (c) any form of CRCR.ResultsPPV, sensitivity, NPV, specificity and accuracy of PET in detecting intra-abdominal extra-hepatic CRCR were, respectively, 85.7%, 85.7%, 88.9%, 88.9%, and 87.5% compared with 92.9%, 92.9%, 94.5%, 94.5%, and 93.8%, respectively, for PET/CT. The corresponding values for the detection of extra-abdominal and/or hepatic CRCR were 84.6%, 84.6%, 89.5%, 89.5%, and 87.5% for PET versus 100%, 92.3%, 95%, 100%, and 96.9% for PET/CT. For all forms of recurrence, the corresponding values for PET were 80%, 80%, 66.7%, 66.7%, and 75%, respectively, compared with 94.5%, 90%, 84.6%, 91.7%, and 90.6%, respectively, for PET/CT.ConclusionPET/CT enhances the accuracy and specificity of diagnosis of CRCRa. PET/CT grows to reach prominent roles for imaging and restaging of patients after colorectal carcinoma resection.
    06/2012; 43(2):129–137. DOI:10.1016/j.ejrnm.2012.01.001

Full-text (2 Sources)

Available from
Jul 9, 2014